Usefulness of ultra‑sensitive prostate‑specific antigen following radical prostatectomy

Furubayashi,Nobuki; Negishi,Takahito; Kashiwagi,Eiji; Hirata,Yu; Taguchi,Kenichi; Hasegawa,Yoshihiro; Nakamura,Motonobu

doi:10.3892/mco.2014.310

September-October 2014 Volume 2 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-October 2014 Volume 2 Issue 5

Full Size Image

Article

Usefulness of ultra‑sensitive prostate‑specific antigen following radical prostatectomy

Authors:
- Nobuki Furubayashi
- Takahito Negishi
- Eiji Kashiwagi
- Yu Hirata
- Kenichi Taguchi
- Yoshihiro Hasegawa
- Motonobu Nakamura
View Affiliations / Copyright

Affiliations: Department of Urology, National Kyushu Cancer Center, Fukuoka 811‑1395, Japan, Department of Pathology, National Kyushu Cancer Center, Fukuoka 811‑1395, Japan, Gengen-do Urological Clinic, Usa 879-0471, Japan
Pages: 851-857
|
Published online on: June 12, 2014

https://doi.org/10.3892/mco.2014.310
Expand metrics +

Abstract

This study aimed to evaluate the usefulness of ultra‑sensitive prostate‑specific antigen (PSA) following radical prostatectomy (RP). Between September, 2003 and March, 2009, a total of 311 prostate cancer patients underwent antegrade RP; following the exclusion of 111 patients due to prior hormonal therapy, 200 patients were finally included in this study. The results of the multivariate analysis identified RP Gleason score, extraprostatic extension, lymph node metastasis and PSA nadir as significant predictors of biochemical failure (P=0.0116, 0.0216, 0.0178 and <0.0001, respectively) and PSA nadir <0.008 ng/ml exhibited the highest hazard ratio (HR) [HR=26.34; 95% confidence interval (CI): 7.34‑104.69]. After a median follow‑up period of 52.2 months, the biochemical failure‑free rate in the PSA nadir <0.008 and ≥0.008 ng/ml groups was 94.3 and 58.8%, respectively, with a statistically significant difference according to the log‑rank test (P<0.001). In the multivariate analysis, statistically significant differences were observed only in pathological nodel stage within the PSA nadir <0.008 ng/ml group (P=0.0107). For this reason, postoperative follow‑up using ultra‑sensitive PSA is considered to be of value, since the use of high‑sensitivity PSA to confirm a reduction to below postoperative measurement threshold value (PSA nadir <0.008 ng/ml) may avert administering unnecessary additional treatment, regardless of pathological reccurrence factors.

View Figures

View References

1	Polascik TJ, Oesterling JE and Partin AW: Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol. 162:293–306. 1999. View Article : Google Scholar : PubMed/NCBI
2	Kinoshita H, Kamoto T, Nishiyama H, Nakamura E, Matsuda T and Ogawa O: Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males. Int J Urol. 14:930–934. 2007. View Article : Google Scholar
3	Ellis WJ, Vessella RL, Noteboom JL, Lange PH, Wolfert RL and Rittenhouse HG: Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology. 50:573–579. 1997. View Article : Google Scholar : PubMed/NCBI
4	Yu H, Diamandis EP, Prestigiacomo AF and Stamey TA: Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin Chem. 41:430–434. 1995.
5	Haese A, Huland E, Graefen M, Hammerer P, Noldus J and Huland H: Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. J Urol. 161:1206–1211. 1999. View Article : Google Scholar : PubMed/NCBI
6	Sandler HM and Eisenberger MA: Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol. 178:S20–S24. 2007. View Article : Google Scholar : PubMed/NCBI
7	Naito S: Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer. Jpn J Clin Oncol. 35:365–374. 2005. View Article : Google Scholar : PubMed/NCBI
8	Mottet N, Bellmunt J, Bolla M, et al: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 59:572–583. 2011. View Article : Google Scholar
9	Epstein JI, Allsbrook WC Jr, Amin MB and Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242. 2005. View Article : Google Scholar : PubMed/NCBI
10	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumors. 7th edition. Wiley-Blackwell; Oxford: 2009
11	Thompson IM, Tangen CM, Paradelo J, et al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 181:956–962. 2009. View Article : Google Scholar
12	Bolla M, van Poppel H, Tombal B, et al: Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 380:2018–2027. 2012. View Article : Google Scholar
13	Shen S, Lepor H, Yaffee R and Taneja SS: Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol. 173:777–780. 2005. View Article : Google Scholar
14	Nakamura M, Hasumi H, Miyoshi Y, Sugiura S, Fujinami K, Yao M, Kubota Y and Uemura H: Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy. Int J Urol. 12:1050–1054. 2005. View Article : Google Scholar : PubMed/NCBI
15	Bader P, Burkhard FC, Markwalder R and Studer UE: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol. 169:849–854. 2003. View Article : Google Scholar
16	Shimizu F, Tanaka S, Matsuyama Y, Tominaga T, Ohashi Y and Fujime M: Efficiency of ultrasensitive prostate-specific antigen assay in diagnosing biochemical failure after radical prostatectomy. Jpn J Clin Oncol. 37:446–451. 2007. View Article : Google Scholar : PubMed/NCBI
17	Terai A, Matsui Y, Yoshimura K, Arai Y and Dodo Y: Salvage radiotherapy for biochemical recurrence after radical prostatectomy. BJU Int. 96:1009–1013. 2005. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Usefulness of ultra‑sensitive prostate‑specific antigen following radical prostatectomy

This article is mentioned in:

Abstract

Figure 1

Related Articles